Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared with BGF MDI HFA

Trial Identifier: D5985C00005
Sponsor: AstraZeneca
Collaborator:
Parexel
NCTID:: NCT05477108
Start Date: July 2022
Primary Completion Date: April 2023
Study Completion Date: April 2023
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, MD Brooklyn, MD, US, 21225